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DETERMINING THE INTERACTION OF
Atg11CC2-3 WITH ITS PROTEIN PARTNERS
USING IN VITRO BINDING ASSAYS

Jesse E. Smith
Dr. Steven Backues, Mentor
ABSTRACT
Autophagy is a mechanism of cellular upkeep by trafficking
intracellular material to be degraded. Autophagy is known to
be carried out by autophagy related proteins (Atg), yet the exact
mechanism of how autophagy occurs has yet to be discovered. Due
to its clinical relevance to conditions such as neurodegenerative and
muscular diseases, a great deal of current research is being dedicated
to further our understanding of how autophagy occurs. Atg11, a
protein critical to a yeast’s ability to perform selective autophagy,
may also hold many answers to selective autophagy within humans.
Atg11 is a coiled-coil protein that interacts with Atg1, 9, 11, 20, 29,
along with Ypt1 in selective autophagy. However, it is unknown
how these interactions occur. Does Atg11 have multiple binding
sites where it may bind to proteins simultaneously? Or does Atg11
have one competitive binding site where it can only bind with a
single protein, and then release it before it may bind again? In this
research we attempt to purify the binding portion of Atg11 so that
it can be used to observe Atg11’s binding interactions with these
proteins through a protein binding test mediated by a resin pulldown.

INTRODUCTION
Neurodegenerative diseases in humans fall beyond the
reach of most current means of pharmaceutical interventions.
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With advancements in treatments for cancer and cardiovascular
diseases, the life expectancy of many individuals is expected to
increase (1). An increase in life expectancy may also increase the
likelihood of developing a neurodegenerative disease. As one’s
age and life expectancy increases, the amount of years their
neurons and muscle cells (myofibrils) have been in existence
increases, as well. This is because neurons and myofibrils lack the
ability to undergo cell division (2). With cellular division being
the primary means for the regeneration of tissues, non-dividing
cells must possess a different means to aid in their survival over
the course of one’s lifespan.
Longevity in nervous and muscle tissue is thought to
be correlated to a cell’s ability to maintain proper function. In
nervous and muscle tissue, to maintain proper function, a large
sum of energy produced from the mitochondria is required. A
buildup of waste and free radicals that damage cellular structures
is more likely because of mitochondrial activity (3). Lysosomal
degradation compensates for this by aiding in the degradation and
recycling of damaged cellular material (4).
Macroautophagy (referred to as “autophagy”) is a
process that aids the lysosome in cleaning up these damaged
cell structures (5). Autophagy describes an intracellular process
in which material is wrapped in a double membrane vesicle,
known as an autophagosome (Figure 1), and transported for
degradation in either a lysosome (in animals), or vacuole (in
other eukaryotes) (6). The two primary categories of autophagy
describe the intracellular content being packaged for degradation.

Figure 1: General depiction of autophagy within mammalian cells. Autophagy is process in which
intracellular material is wrapped into a double membrane vesicle known as an autophagosome and
transported to be degraded. (Figure adapted from reference 8).
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Bulk autophagy describes an intracellular response to starvation
in which a large amount of non-specific material is packaged and
sent for degradation. In contrast, selective autophagy describes
a process in which a specific cargo is recognized as needing to
be degraded (7). Though both forms of autophagy are vital for
cellular survival, selective autophagy attracts attention from
researchers due to its implications for neurodegenerative diseases.
Further delineation of selective autophagy has occurred
through these investigations. Selective autophagy may be
categorized in regards to the size of its payload to be degraded
(7). Additional classifications of selective autophagy are made
by describing the actual content being transported (9). Through
xenophagy eliminating pathogenic structures within a cell,
aggrephagy eliminating denatured polyubiquitinated proteins,
mitophagy eliminating damaged mitochondria, and lipophagy
specifically targeting lipids for degradation, no cellular content
seems to fall outside of the reach of autophagy. For this reason, a
dysfunction in the cell’s ability to perform autophagy may lead to a
buildup of dysfunctional intracellular content.
A cell’s ability to perform autophagy effectively has been
found to both aid and hinder a diseased individual, depending on
the situation (4)(10)(11)(12)(13). Autophagy possesses a multifaceted role in cancer. In breast, prostate, and ovarian cancer
victims, disruption of an autophagy regulatory complex known as
monoallelic Beclin 1 on chromosome 17q21 has been found in 40
to 75% of patients (11). Additionally, a cell that lacks in the ability
to perform mitophagy may experience a buildup of metabolic
waste due to mitochondrial dysfunction, which puts additional
stressors on DNA, increasing the chance of damage (14). Once
cancer tumors develop, the ability to perform autophagy may
increase the likelihood of survival for a tumor in times of nutrient
deprivation(12).
In neurodegenerative diseases, mitochondrial dysfunction
and an accumulation of protein aggregates are two aspects of
pathogenesis that can be prevented by autophagy (15)(16). An
accumulation of dysfunctional proteins with polyglutamine rich
protein extensions blocks certain autophagy pathways, rendering a
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cellular response to this protein build up impossible (9). Additional
buildup of proteins that interfere with autophagic pathways and
lysosome function progress the development of both Huntington’s
and Alzheimer’s disease (16)(18). Pharmaceutical intervention to
induce autophagy aids in treating these diseases’ pathogenesis.
However, there are limited options (14)(17).
Autophagy related proteins (Atg) are thought to provide
the answer to many of these questions regarding the buildup of
cellular debris (1). Atg proteins, along with additional factors,
are known to induce autophagy. There are over 35 known Atg
proteins, half of which are vital to autophagy. Based on their
function, certain Atg proteins are categorized as necessary for
bulk or selective autophagy. Of these Atg proteins, Atg11’s role
in selective autophagy will be the focus of this research. Atg11 in
yeast functions as a scaffolding protein that aids in the production
of the autophagosome assembly site. Atg11 does this by binding
to a variety of partners, including Atg17, Atg9, and Atg1 (Figure
2), in addition to cargo receptors allowing for the autophagosome
to be formed (18)(19). It is known that the coiled coil domains two
through three (CC2-3) are required for Atg11’s self-interaction,
along with its interactions with Atg1 (19). The extent of these

Figure 2: Atg11’s interactions by coil-coiled domain: This diagram shows the interactions of
Atg11 through its coiled-coil domains 2-3. Figure courtesy Dr. Steven Backues.

interactions, however, is not understood.
This study will aid in further understanding of Atg11 in
yeast, which in turn will aid in understanding autophagy related
proteins in humans. By furthering the understanding of Atg11’s
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role within selective autophagy in yeast, it is hoped that the role of
its homologs (Huntingtin and FIP200) can be further understood
within humans (20). The goal of this research is to gain insight in
Atg11’s scaffolding ability. Does Atg11 bind to multiple partners
at once? Or, is Atg11 limited to one binding site in which inhibition
may occur between other Atg partners?

RESULTS
In an effort to use ligase independent cloning to produce
an expression clone of ATG11 CC2-3, a Polymerase Chain
Reaction was performed (PCR). The goal of our PCR was to
amplify the ATG11 CC2-3 region. The region amplified in the
PCR is from base pair 961 to 2577, corresponding to amino

Figure 3: ATG11CC2-3b inserts amplified from genomic yeast DNA (lane 2) and recombinant
plasmid DNA (lane 3). Through PCR amplification using genomic yeast and plasmid DNA, the
ATG11CC2-3b gene was amplified (amino acids 321-859 corresponding to roughly 1600 base
pairs). Plasmid DNA yielded a large band at 1600 base pairs, as visualized by DNA electrophoresis.

acids 321-859 on Atg11, previously reported to correspond to
the CC2-3 region by Lippotova (8). One template was genomic
yeast DNA (fryf43sas2Δ) and the other template was a plasmid
containing ATG11 (pRS414-ATG11-19-23-27). The completed
PCR reactions were separated on a 2% agarose gel (Figure 3).
Plasmid pRs414-ATG11-19-23-27 yielded an intense band at
around 1600bp, which is the expected size for ATG11CC2-3b.
For this reason, this PCR product was selected as the insert for the
ligation independent cloning (Figure 3).
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Following PCR, the selected PCR product was purified
using a PCR purification kit, and the concentration of the purified
DNA was found to be 270ng/ul. T4 treatment of the DNA was then
performed; the goal of this was to eliminate flanking base pairs to
prepare the “sticky” ends of the DNA so it could be inserted into
the pMCSG10 E. coli vector. To complete the ligation independent
cloning, the T4 treated insert was then annealed with the linearized,
T4 treated pMCSG10 vector and transformed into DH5α competent
cells. Four colonies were picked from the plate, and the DNA
was purified by a miniprep procedure. To determine which of the
selected colonies contained the desired insert, each of the four DNA
clones isolated by miniprep was amplified by PCR using primers
recognizing ATG11CC2-3b, and the PCR products were separate
on a 2% agarose gel (Figure 4). Since bands from all four clones
were seen at around 2000bp, each clone was sequenced.
Unfortunately, analysis of the sequencing results revealed
a frameshift mutation in all of the samples, which could be traced
back to an error in the design of the primers initially used to
2000BP
1200BP

Ladder
Figure 4: pMCSG10-ATG11CC2-3 present in transformed E. coli. A 2% gel was run of
a PCR of 4 transformed colonies (C1-4) checking for the presence of ATG11CC2-3b in
pMCSG10. The positive control (+) was another plasmid that also contained this region,
pMCSG10-Atg11CC2-3a while the negative control (-) was an empty pMCSG10 vector. It
was found that ATG11CC2-3b was present in all four clones.

amplify the ATG11CC2-3b insert (Figure 5).
Therefore, the initial PCR amplification was repeated
using the same template but with corrected primers. The PCR
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Figure 5: Primer error for ATG11CC2-3b. Showing the error in primer 226 (bottom strand)
compared to our pMCSG10-ATG11CC2-3b design (top strand). The primer includes 20
base pairs out of frame starting at base pair 7380 of the ATG11 gene. Since 20 is not a
multiple of 3, this led to a frameshift mutation that added an additional 33 erroneous amino
acids before a stop codon was reached.

products were run on a 2% gel following the amplification of
ATG11CC2-3b using the new primers (Figure 6).
As one may see, at 1600bp in lane two there is a band
leading one to believe that the desired ATG11CC2-3b fragment

3000BP

1000BP

Atg11CC-3b
Figure 6: Atg11CC2-3b amplified via PCR using new primers ATG11CC2-3b was
amplified by PCR using new primers, and the product and checked on a 2% agarose gel
versus a standard 1KB ladder.

was produced. A PCR purification procedure was performed on
this DNA, yielding a concentration of 33 ng/ul, followed by T4
treatment of this DNA, and then annealing it to pMCSG10 and
transforming the plasmid into DH5alpha cells. Following the
transformation, three colonies were selected and the DNA isolated
by miniprep. The presence of the insert was verified by PCR
with primers recognizing ATG11CC2-3b, and the products were
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separated via a 1% agarose gel (Figure 7).
ATG11CC2-3b appeared to be present in all three clones,
so they were sent for sequencing. Positive sequencing results
2000BP
1200BP

Ladder

Colony 1

Colony 2

Colony 3

Figure 7: pMCSG10-ATG11CC2-3b expressed in E. coli. A 2% gel of a PCR checking
for ATG11CC2-3b in each of three putative clones of pMCSG10-ATG11CC2-3b, each
isolated from an individual transformed colony . Each colony appeared to have a band at
roughly 1600 base pairs representing ATG11CC2-3b.

demonstrated that pMCSG10-ATG11CC2-3b had been successfully
created with no frameshift mutations or other errors (Figure 8).
A sample of pMCSG10-ATG11CC2-3b DNA was
transformed into Rosetta competent cells, with the goal of

Figure 8: Sequencing Results using the new primers. Analysis of cloning sequencing results
using primers 221 (binding region highlighted in red representing the forward sequence) and 246
(binding region highlighted in light blue representing the reverse sequence Sequencing results
confirmed presence of base pairs 961 to 2577 of Atg11, which code for the CC2-3b region.
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producing as much purified Atg11CC2-3b protein as possible.
The Rosetta cells were induced overnight via auto induction and
lysed via sonication. Following lysis, the content of the cells was
separated into soluble, insoluble, and glutathione resin-bound
fractions. The glutathione-S transferase (GST) is encoded in the
pMCSG10 vector, so that the Atg11CC2-3 protein is produced
with GST attached, thereby allowing the protein to bind to the
glutathione resin. Following lysis and fractionation, a 12.5% SDS

Figure 9: Atg11CC2-3b does not express well in E. coli. pMCSG10-Atg11CC2-3b was
transformed into Rosetta cells and induced through autoinduction to express Atg11CC23b. The cells were lysed and separated into soluble (S), insoluble (I), and glutathione resin
bound (B) fractions and samples were run on a 12.5% SDS page gel. The positive control
was a previously produced version of Atg11CC2-3a (+), while the negative control was
pMCSG10-empty. No band corresponding to Atg11CC2-3b could be seen, suggesting that
it does not express at sufficient levels.

page gel of the soluble, insoluble, and resin bound fraction of the
cells proteins was run.
The negative control is the GST alone from the empty
pMCSG10 vector. The negative control bound sample has a band
in the right region for GST, indicating that autoinduction worked,
and the resin binding was effective. The positive control, however,
did not produce a band within the GST bound lane, indicating
expression of Atg11CC2-3a did not occur. In addition, it appears
that the cell lysis is not occurring as effectively as we would like,
due to the fact that the soluble lane does not contain as much
material as it would if all the cells were to lyse.
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DISCUSSION
Sequencing results confirmed the successful creation of
pMCSG10-ATG11CC2-3b within our strains of E. coli. However,
since Atg11CC2-3b protein was not seen in a small scale resin binding
test, our protocol for protein expression proved to be inadequate.
Similar projects were done in our laboratory using various ATG11
constructs, with pMCSG10-ATG11CC2-3a being the only construct
found to express Atg11. Other expression projects in our laboratory
centered on Atg11, including the project discussed in this paper,
have all failed to produce Atg11 at adequate concentration, purity,
and stability to test for protein interactions using biochemical means.
The failure to express and purify Atg11CC2-3b in E. coli has led
our laboratory to rethink our methods. Moving forward, we as a
laboratory are transitioning to using a yeast two hybrid assay to test for
interactions of Atg11 and its binding partners. This is an established
approach that does not require the expression and purification of any
proteins, but instead uses various autophagy related proteins attached
to a DNA binding domain within yeast, and various ATG11 constructs
attached to an activating domain.

METHODS
Vector selection:
The expression vector pMCSG10 was created by the
Midwest Center for Structural Genomics and was a gift of Dr.
Hana Popelka (Laboratory of Dr. Daniel Klionsky, University of
Michigan) (22). Its key features area T7 promoter, an N-terminal
Glutathione-S-Transferase (GST) tag, and a Ligation Indpendent
Cloning (LIC) compatible multiple cloning site.

Atg11 Insert Production by PCR:
Primers were designed to produce an ATG11CC2-3b
insert (base pairs 961-2577 of the Atg11 coding sequence) through
ligation independent cloning (Table 1). Primers SKB221 and
SKB226 were used for insert produced in Figure 3 and checked
in Figure 4, while SKB221 and SKB246 were used for the insert
in Figure 5 and checked in Figure 7. DNA to be amplified was
supplied by E. coli plasmid pRS414-ATG11-19-23-27. The PCR
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was performed using Phusion DNA polymerase (New England
Biolabs) according to manufacturer’s protocol.
Primer Name

Primer Function

Primer Sequence

SKB221

Forwards primer for LIC cloning of
ATG11CC2 (a.a. 321)

tac ttc caa tcc aat gca CAA ATG
TTT ACC CCG AAT GAA TC

SKB226

Incorrect reverse primer for LIC cloning of
ttatccacttccaatgtta
ATG11CC3 (a.a. 859)
GAGGAATGGTTTCGAATTTCTCA

SKB246

Corrected Reverse primer for LIC cloning
of ATG11CC3 (a.a. 859)

ttatccacttccaatgttaACCTTTTT
CCATCGAGCTTGAG

Table 1: Primers used for PCR amplification of Atg11CC2-3b:

DNA Gel Electrophoresis:
Electrophoresis was performed at 120V using TAE buffer
and an agarose gel. 1% gels were made using 50mL of buffer, 0.5g
of agarose (1g in 2% gels), and 1.5ul of Gel Red (Biotium). Gels
were imaged with a BioRad ChemiDoc XRS+ Molecular Imager
using the manufacturer’s protocol.

T4 Treatment:
T4 processing was used to eliminate bases at the end of both
our insert (ATG11CC2-3b) and vector (pMCSG10) to create overlap
between the two strands. T4 DNA Polymerase was purchased from
ThermoFisher. The T4 treatment consisted of a PCR cycle consisting
of 35 minutes at 22°C, 20 minutes at 75°C, and then cooling on ice.
The reaction mixture for the T4 treatment of pMCSG10 included 5ul
of linearized plasmid, 12ul of 5x buffer, 3ul of 100mM DTT, 2.5ul of
100mM dGTP, 1.5ul of T4 DNA polymerase, and 35ul of dH20. The
reaction mixture for the T4 reaction of Atg11CC2-3b included 5ul of
insert, 12ul of 5x buffer, 3ul of 100mM DTT, 2.5ul of 100mM dCTP,
1.5ul of T4 DNA polymerase, and 35ul of dH20.

Insert Annealing to Vector:
Annealing of the ATG11CC2-3b to pMCSG10 occurred
by mixing 1ul of T4-treated plasmid with 2ul of T4-treated insert,
incubating for 10 minutes at 22°C, adding 1ul of 25mM EDTA,
incubating for five minutes at 22°C, and then holding on ice until
ready for use.
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Transformation into E. coli cells
Transformation of the annealed construct into E. coli
DH5α cells started with thawing 100ul of competent cells on ice
for five minutes, adding 1ul of DNA, incubating for 30 minutes
on ice, heat shocking for 42 seconds at 42°C, incubating on ice for
two minutes, and then suspending in 1mL of SOB and incubating
with rotation at 37°C for an hour. 100ul of mixture was spread
on one plate (10% plate), while the other 900ul was pelleted
via centrifugation at 13,000 RPM in a Sorvall Biofuge Pico and
resuspended in 100ul of SOB then plated (90% plate). Plates were
incubated for 24 hours at 37°C.

Small Scale Resin Binding Test:
Autoinduction was used to induce E. coli containing
the construct into producing Atg11CC2-3b (21). Autoinduction
occurred in autoinduction media containing 1% tryptone, 0.5%
yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl,
5mM Na2SO4, 0.5% glycerol, 0.2% α-lactose, 0.05% glucose,
and 2 mM MgSO4. The autoinduction media was prepared with
carbenicillin (50ug/ml) and chloramphenicol (34ug/ml) and
inoculated. The cultures were grown overnight, harvested by
centrifugation at 12,000g for 1 minute, washed with a solution
of 25mM HEPES pH 7, 150mM NaCl, and 5% glycerol (known
as PEB1), and re-suspended in 1ml PEB1 with 10mM β–ME
and 1mM PMSF. The cells were lysed via sonication at three ten
second pulses at a power level of 4 with 30 seconds cooling on ice
between pulses. Fifty (50)ul of 20% TX-100 detergent were added
to the mixture and the mixture was vortexed. Samples were then
centrifuged for 10 minutes at 10,000g and 4°C. The supernatant
(soluble fraction) was removed and saved for further processing.
The pellet was then suspended in 200ul of 2xSSB (insoluble
fraction). Twenty-five percent (25%) glutathione resin in PEB1
was added to the supernatant to bind with the GST tag (bound
fraction). This solution was mixed for 30 minutes at 4°C, then the
resin was isolated by centrifugation at 300g for 1 minute at 4°C,
washed three times with PEB1+1% TX-100+10mM β-ME+1mM
PMSF, re-suspended by inversion and washed with PEB1+10mM
β-ME+1mM PMSF. The buffer was removed and 25ul of 2xSSB
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was added. Samples of the soluble and insoluble fractions for
SDS-page analysis were prepared by combining 20ul of each
fraction with 20ul of 2xSSB. SDS page gels (12.5%) were run
at 120V, stained with Coomassie Blue, and imaged in a BioRad
ChemiDoc XRS+ Molecular Imager.
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